

Similarly, animal models for certain infections are available. Animal models for infectious diseases include the woodchuck (82), which is the animal model of choice for hepatitis B virus, the chimpanzee (83), which is an appropriate large-animal model for HCV, and the armadillo (84), which is the animal model for *Mycobacterium leprae*, the cause of leprosy (Hansen's disease). A suitable small-animal model for hepatitis C infections has not yet been found.

In proposing and using animal models for disorders that have an immune component, it is useful to be aware of the similarities (and differences) between the mouse immune system and the human immune system. Mestas and Hughes (85) outline some of these similarities

and differences. Researchers conducting animal models on diseases with an immune component, that is, cancer, autoimmune diseases, and inflammatory disorders, need to be aware of similarities and differences in the immune systems between their animal and humans. For example, comparisons between mouse and human dendritic cells (86), T cells (87), B cells (88), NK cells (89), macrophages (90), eosinophils (91), and toll-like receptors (TLRs) (92), are available.

Animal models for immune disorders include the following. A rodent model for multiple sclerosis, called EAE (93), involves injecting animals with myelin basic protein (94). A mouse model for rheumatoid arthritis involves injecting

⁸²Menne S, Cote PJ. The woodchuck as an animal model for pathogenesis and therapy of chronic hepatitis B virus infection. *World J. Gastroenterol.* 2007;13:104–24.

⁸³Bukh J, Thimme R, Meunier JC, et al. Previously infected chimpanzees are not consistently protected against reinfection or persistent infection after reexposure to the identical hepatitis C virus strain. *J. Virol.* 2008;82:8183–95.

⁸⁴Hamilton HK, Levis WR, Martiniuk F, Cabrera A, Wolf J. The role of the armadillo and sooty mangabey monkey in human leprosy. *Int. J. Dermatol.* 2008;47:545–50.

⁸⁵Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. *J. Immunol.* 2004;172:2731–8.

⁸⁶Boonstra A, Asselin-Paturel C, Gilliet M, et al. Flexibility of mouse classical and plasmacytoid-derived dendritic cells in directing T helper type 1 and 2 cell development: dependency on antigen dose and differential toll-like receptor ligation. *J. Exp. Med.* 2003;197:101–9.

⁸⁷Walzer T, Arpin C, Beloeil L, Marvel J. Differential in vivo persistence of two subsets of memory phenotype CD8 T cells defined by CD44 and CD122 expression levels. *J. Immunol.* 2002;168:2704–11.

⁸⁸Frasca D, Landin AM, Riley RL, Blomberg BB. Mechanisms for decreased function of B cells in aged mice and humans. *J. Immunol.* 2008;180:2741–6.

⁸⁹Ehrlich LI, Ogasawara K, Hamerman JA, et al. Engagement of NKG2D by cognate ligand or antibody alone is insufficient to mediate costimulation of human and mouse CD8 + T cells. *J. Immunol.* 2005;174:1922–31.

⁹⁰Sunderkötter C, Nikolic T, Dillon MJ, et al. Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response. *J. Immunol.* 2004;172:4410–7.

⁹¹Dyer KD, Percopo CM, Xie Z, Yang Z, et al. Mouse and human eosinophils degranulate in response to platelet-activating factor (PAF) and lysoPAF via a PAF-receptor-independent mechanism: evidence for a novel receptor. *J. Immunol.* 2010;184:6327–34.

⁹²Janssens S, Beyaert R. Role of Toll-like receptors in pathogen recognition. *Clin. Microbiol. Rev.* 2003;16:637–46.

⁹³Mix E, Meyer-Rienecker H, Zettl UK. Animal models of multiple sclerosis for the development and validation of novel therapies—potential and limitations. *J. Neurol.* 2008;255(Suppl. 6):7–14.

⁹⁴Zaller DM, Osman G, Kanagawa O, Hood L. Prevention and treatment of murine experimental allergic encephalomyelitis with T cell receptor V beta-specific antibodies. *J. Exp. Med.* 1990;171:1943–55.